LeMaitre Vascular (NASDAQ:LMAT) Hits New 52-Week Low - Should You Sell?

Key Points

• LeMaitre Vascular fell to a new 52-week low of $78.39, well below its 50-day and 200-day moving averages of $94.14 and $99.62, respectively.
• Analyst sentiment is mixed but leans cautious: three analysts rate the stock Buy and six Hold, producing a consensus Hold rating with a $110.60 target price.
• The company missed quarterly earnings and revenue estimates, reporting $0.74 in EPS versus $0.81 expected, but revenue still increased 9.6% year over year; it also declared a $0.25 quarterly dividend, equivalent to a 1.3% yield.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $78.39 and last traded at $78.9630, with a volume of 252422 shares. The stock had previously closed at $79.96.

Analysts Set New Price Targets

Several brokerages have recently weighed in on LMAT. Weiss Ratings lowered LeMaitre Vascular from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Friday, August 14th. Citizens Jmp raised their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a "market outperform" rating in a report on Wednesday, May 6th. Wall Street Zen downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Wells Fargo & Company reduced their price target on shares of LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating for the company in a research report on Wednesday, August 5th. Finally, Citigroup reiterated a "market outperform" rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $110.60.

LeMaitre Vascular Stock Performance

The firm has a market cap of $1.81 billion, a price-to-earnings ratio of 27.71, a price-to-earnings-growth ratio of 2.36 and a beta of 0.53. The company has a quick ratio of 13.96, a current ratio of 16.31 and a debt-to-equity ratio of 0.40. The stock has a fifty day moving average price of $94.14 and a 200-day moving average price of $99.62.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing analysts' consensus estimates of $0.81 by ($0.07). The firm had revenue of $70.38 million during the quarter, compared to analysts' expectations of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business's quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the business earned $0.60 earnings per share. On average, analysts expect that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Thursday, August 20th will be paid a $0.25 dividend. The ex-dividend date is Thursday, August 20th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.3%. LeMaitre Vascular's payout ratio is 35.09%.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors have recently made changes to their positions in the stock. Sound Income Strategies LLC increased its holdings in shares of LeMaitre Vascular by 425.6% in the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 183 shares in the last quarter. Catalyst Capital Advisors LLC purchased a new stake in LeMaitre Vascular during the first quarter worth about $32,000. Geneos Wealth Management Inc. boosted its holdings in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after buying an additional 398 shares in the last quarter. EverSource Wealth Advisors LLC acquired a new position in LeMaitre Vascular during the second quarter worth about $47,000. Finally, Quarry LP grew its position in LeMaitre Vascular by 267.2% during the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier's stock worth $64,000 after buying an additional 529 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source